Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a neuromuscular blocker presented as a sterile injectable for intramuscular use. It temporarily reduces muscle activity by inhibiting acetylcholine release and is employed in several therapeutic and aesthetic indications.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letybo is a botulinum toxin type A product that acts on the neuromuscular junction to manage several disorders. - Cervical dystonia: reduces abnormal neck muscle contractions and pain. - Chronic migraine: decreases frequency of migraine days when injected in specific head muscles. - Upper‑limb spasticity: improves range of motion by relaxing overactive forearm muscles. - Hyperhidrosis: diminishes excessive sweating in the underarms. - Glabellar lines (cosmetic): smooths frown lines by relaxing forehead muscles.

Adverse reactions are generally related to the injection site and the pharmacologic action of the toxin.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection point. - Bruising: localized discoloration due to minor bleeding. - Headache: transient headache following treatment. - Flu‑like symptoms: low‑grade fever or malaise. - Localized muscle weakness: temporary reduction in strength of nearby muscles. - Dry mouth: reduced salivation in the treated area.

Serious or Rare Side Effects: - Dysphagia: difficulty swallowing that may require medical attention. - Respiratory compromise: weakness of respiratory muscles leading to breathing difficulty. - Anaphylaxis: severe allergic reaction with rash, swelling, or airway obstruction. - Spread of toxin effect: systemic weakness affecting distant muscles. - Botulism‑like syndrome: generalized weakness, vision changes, or drooping eyelids. - Severe infection: cellulitis or abscess at the injection site.

Prior to administration, clinicians should evaluate patient history and specific risk factors. - Infection at injection site: avoid injecting into areas with active infection. - Known hypersensitivity: do not use in patients with allergy to botulinum toxin or its excipients. - Neuromuscular disorders: caution in patients with myasthenia gravis, Lambert‑Eaton syndrome, or ALS. - Pregnancy and breastfeeding: safety not established; use only if potential benefit justifies risk. - Elderly or debilitated patients: start with lower doses and monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A may interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin): can potentiate neuromuscular blockade. - Quinolone antibiotics (e.g., ciprofloxacin): may increase risk of muscle weakness. - Other neuromuscular blocking agents (e.g., curare, pancuronium): additive effect leading to severe paralysis.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., verapamil): may enhance toxin spread. - Anticholinergic drugs (e.g., atropine): could modify clinical response. - Concurrent botulinum toxin products: cumulative dosing may increase adverse events.